Hikma Pharmaceuticals Statistics
Hikma Pharmaceuticals (H5P) Stock Statistics & Valuation Metrics
Total Valuation
Hikma Pharmaceuticals has a market cap or net worth of EUR 4.02B. The enterprise value is EUR 4.59B.
- Market Cap
- EUR 4.02B
- Enterprise Value
- EUR 4.59B
Share Statistics
Hikma Pharmaceuticals has 208,747,630 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 208,747,630
- Owned by Insiders
- 12.11%
- Owned by Institutions
- 15.68%
Financial Efficiency
Hikma Pharmaceuticals’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 10.49%.
- Return on Equity (ROE)
- 0.16
- Return on Assets (ROA)
- 0.07
- Return on Invested Capital (ROIC)
- 10.49%
- Return on Capital Employed (ROCE)
- 0.14
- Revenue Per Employee
- 352.53K
- Profits Per Employee
- 43.20K
- Employee Count
- 9,500
- Asset Turnover
- 0.59
- Inventory Turnover
- 1.72
Valuation Ratios
The current PE Ratio of Hikma Pharmaceuticals is 12.12. Hikma Pharmaceuticals’s PEG ratio is -0.12.
- PE Ratio
- 12.12
- PS Ratio
- 1.32
- PB Ratio
- 1.81
- Price to FCF
- 30.31
- Price to Operating Cash Flow
- 11.58
- PEG Ratio
- -0.12
Income Statement
In the last 12 months, Hikma Pharmaceuticals had revenue of 3.35B and earned 410.43M in profits. Earnings per share was 1.86.
- Revenue
- 3.35B
- Gross Profit
- 1.44B
- Operating Income
- 579.92M
- Pretax Income
- 529.89M
- Net Income
- 410.43M
- EBITDA
- 845.00M
- Earnings Per Share (EPS)
- 1.86
Cash Flow
In the last 12 months, operating cash flow was 396.55M and capital expenditures -248.38M, giving a free cash flow of 148.17M billion.
- Operating Cash Flow
- 396.55M
- Free Cash Flow
- 148.17M
- Free Cash Flow per Share
- 0.70
Dividends & Yields
Hikma Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of 3.73%
- Dividend Per Share
- ―
- Dividend Yield
- 3.73%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 3.29%
- Earnings Yield
- 8.38%
Stock Price Statistics
- Beta
- 0.53
- 52-Week Price Change
- 12.16%
- 50-Day Moving Average
- 19.13
- 200-Day Moving Average
- 17.23
- Relative Strength Index (RSI)
- 48.75
- Average Volume (3m)
- 825
Important Dates
Hikma Pharmaceuticals upcoming earnings date is Feb 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Feb 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Hikma Pharmaceuticals as a current ratio of 1.82, with Debt / Equity ratio of 61.84%
- Current Ratio
- 1.82
- Quick Ratio
- 1.06
- Debt to Market Cap
- 0.34
- Net Debt to EBITDA
- 1.51
- Interest Coverage Ratio
- 5.36
Taxes
In the past 12 months, Hikma Pharmaceuticals has paid 114.35M in taxes.
- Income Tax
- 114.35M
- Effective Tax Rate
- 0.22
Enterprise Valuation
Hikma Pharmaceuticals EV to EBITDA ratio is 6.98, with an EV/FCF ratio of 41.88.
- EV to Sales
- 1.82
- EV to EBITDA
- 6.98
- EV to Free Cash Flow
- 41.88
- EV to Operating Cash Flow
- 15.65
Balance Sheet
Hikma Pharmaceuticals has EUR 290.50M in cash and marketable securities with EUR 1.97B in debt, giving a net cash position of -EUR 1.68B billion.
- Cash & Marketable Securities
- EUR 290.50M
- Total Debt
- EUR 1.97B
- Net Cash
- -EUR 1.68B
- Net Cash Per Share
- -EUR 8.03
- Tangible Book Value Per Share
- EUR 6.68
Margins
Gross margin is 40.88%, with operating margin of 19.41%, and net profit margin of 11.31%.
- Gross Margin
- 40.88%
- Operating Margin
- 19.41%
- Pretax Margin
- 14.93%
- Net Profit Margin
- 11.31%
- EBITDA Margin
- 26.05%
- EBIT Margin
- 19.41%
Analyst Forecast
The average price target for Hikma Pharmaceuticals is EUR 23.10, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 23.10
- Price Target Upside
- 17.04% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- -0.88%
- EPS Growth Forecast
- 0.05%
Scores
- Smart Score
- 10
- AI Score
- ―
